Print Clear

Prior Authorization Request Administrative Information

Member Information

Last name _____ First name _____ MI _____

Member ID _____ Date of birth _____

Sex assigned at birth ☐ Female ☐ Male ☐ "X" or Intersex

Current gender ☐ Female ☐ Male ☐ Transgender male ☐ Transgender female ☐ Other _____

Place of residence ☐ Home ☐ Nursing facility ☐ Other _____

Race/ethnicity _____ Preferred spoken language _____ Preferred written language _____

MassHealth does not exclude people or treat them differently because of race, color, national origin, age, disability, religion, creed, sexual orientation, or sex (including gender identity and gender stereotyping).

Plan Contact Information

Please indicate the member's MassHealth Plan and fax or submit this completed and signed form according to the Plan's contact information below.

MassHealth Fee-For-Service (FFS) Plan, Primary Care Clinician (PCC) Plan, Primary Care Accountable Care Organization (PCACO) Plan, Children's Medical Security Plan, and Health Safety Net Plan
☐ **MassHealth Drug Utilization Review Program** Pharmacy: Fax: (877) 208-7428 - Tel: (800) 745-7318
MassHealth Managed Care Organization (MCO) and Accountable Care Partnership Plans (ACPP)
☐ **Fallon Health** Online Prior Authorization: go.covermymeds.com/OptumRx Online Prior Authorization: providerportal.surescripts.net/ProviderPortal/optum Pharmacy: Fax: (844) 403-1029 - Tel: (844) 720-0033
☐ **Health New England** Online Prior Authorization: go.covermymeds.com/OptumRx Pharmacy: Fax: (800) 550-9246 - Tel: (800) 918-7545
☐ **Mass General Brigham Health Plan** Online Prior Authorization (Non-Specialty Drugs): go.covermymeds.com/OptumRx Online Prior Authorization (Specialty/Medical Drugs): provider.massgeneralbrighamhealthplan.org Pharmacy: Fax: (844) 403-1029 - Tel: (800) 711-4555
☐ **Tufts Health Plan** Online Prior Authorization: point32health.promptpa.com Pharmacy: Fax: (617) 673-0939 - Tel: (888) 257-1985
☐ **WellSense Health Plan** Online Prior Authorization: wellsense.org/providers/ma/pharmacy/prior-authorizations Pharmacy: Fax: (833) 951-1680 - Tel: (877) 417-1822

over

Nonsteroidal Anti-Inflammatory Drugs (NSAID) Prior Authorization Request

MassHealth reviews requests for prior authorization (PA) on the basis of medical necessity only. If MassHealth approves the request, payment is still subject to all general conditions of MassHealth, including current member eligibility, other insurance, and program restrictions. MassHealth will notify the requesting provider and member of its decision. Keep a copy of this form for your records. If faxing this form, please use black ink.

Additional information about these agents, including PA requirements and preferred products, can be found within the MassHealth Drug List at **www.mass.gov/druglist.**

Medication information

Medication requested (Check one or all that apply. Where applicable, the brand name is provided in brackets for reference.)

- ☐ diclofenac 25 mg capsule
- ☐ diclofenac/misoprostol < 60 years of age
- ☐ diclofenac potassium 25 mg tablet
- ☐ diclofenac powder for solution
- ☐ diclofenac topical patch [Flector]
- ☐ Elyxyb (celecoxib oral solution)
- ☐ etodolac extended-release
- ☐ fenoprofen
- ☐ ibuprofen/famotidine < 60 years of age
- ☐ Indocin (indomethacin suspension)
- ☐ ketoprofen extended-release
- ☐ ketorolac > 20 units/30 days
- ☐ ketorolac nasal spray
- ☐ Licart (diclofenac topical patch)
- ☐ meclofenamate
- ☐ meloxicam capsule
- ☐ naproxen controlled-release
- ☐ naproxen suspension < 13 years of age
- ☐ naproxen/esomeprazole < 60 years of age
- ☐ Relafen DS (nabumetone 1000 mg)
- ☐ salsalate
- ☐ tolmetin
- ☐ Zorvolex (diclofenac 18 mg, 35 mg capsule)
- ☐ Other*

Dose, frequency, and duration of medication requested

Indication or ICD-10 code, if applicable

** If request is for a non-preferred brand name or generic product, please attach supporting documentation (e.g., copies of medical records and/or office notes regarding adverse reaction or inadequate response to the preferred product).*

Section I. Please complete for topical product requests.

1. Has the member tried diclofenac 1% gel?
   - ☐ Yes. Please complete Section IV.
   - ☐ No. Please indicate why not.
2. For Licart requests, has the member tried diclofenac topical patch (generic Flector)?
   - ☐ Yes. Please complete Section IV.
   - ☐ No. Please indicate why not.

Section II. Please complete for controlled-release products, extended-release products, solution products, orally disintegrating products, and suspension products.

1. Please provide medical necessity for the use of the requested formulation.

2. For Indocin and naproxen suspension products, has the member tried ibuprofen suspension?
   ☐ Yes. Please complete Section IV.
   ☐ No. Please indicate why not.
3. For diclofenac powder for solution, has the member tried naproxen suspension?
   ☐ Yes. Please complete Section IV.
   ☐ No. Please indicate why not.
4. For Elyxyb, has the member tried celecoxib capsules?
   ☐ Yes. Please complete Section IV.
   ☐ No. Please indicate why not.

Section III. Please complete for diclofenac/misoprostol, ibuprofen/famotidine, ketorolac nasal spray, naproxen/esomeprazole, and Relafen DS requests.

Please attach medical records/office notes documenting medical necessity. A trial with concurrent therapy of diclofenac and misoprostol is required for diclofenac/misoprostol requests. A trial of ketorolac tablets or injection is required for ketorolac nasal spray requests. A trial with concurrent therapy of ibuprofen and famotidine is required for ibuprofen/famotidine requests. A trial with concurrent therapy of naproxen and omeprazole is required for naproxen/esomeprazole requests. A trial of an equivalent dose of nabumetone 500 mg or 750 mg is required for Relafen DS requests.

Section IV. Please complete for all requests as needed.

Please provide the following information regarding previous NSAID trials.*

Drug name Dates/duration of use
Did the member experience any of the following? ☐ Adverse reaction ☐ Inadequate response ☐ Other
Details of adverse reaction, inadequate response, or other.

Drug name Dates/duration of use
Did the member experience any of the following? ☐ Adverse reaction ☐ Inadequate response ☐ Other
Details of adverse reaction, inadequate response, or other.

Drug name Dates/duration of use
Did the member experience any of the following? ☐ Adverse reaction ☐ Inadequate response ☐ Other
Details of adverse reaction, inadequate response, or other.

** Please attach a letter documenting additional trials as necessary.*

over

Section V. Please complete for ketorolac requests exceeding the quantity limit.

Please describe the medical necessity for exceeding the quantity limit.

Section VI. Please complete and provide documentation for exceptions to Step Therapy.

1. Is the alternative drug required under the step therapy protocol contraindicated, or will likely cause an adverse reaction in, or physical or mental harm to the member? ☐ Yes ☐ No

   If yes, briefly describe details of contraindication, adverse reaction, or harm.

2. Is the alternative drug required under the step therapy protocol expected to be ineffective based on the known clinical characteristics of the member and the known characteristics of the alternative drug regimen?
   ☐ Yes ☐ No

   If yes, briefly describe details of known clinical characteristics of member and alternative drug regimen.

3. Has the member previously tried the alternative drug required under the step therapy protocol, or another alternative drug in the same pharmacologic class or with the same mechanism of action, and such alternative drug was discontinued due to lack of efficacy or effectiveness, diminished effect, or an adverse event?
   ☐ Yes ☐ No

   If yes, please provide details for the previous trial.

   Drug name Dates/duration of use

   Did the member experience any of the following? ☐ Adverse reaction ☐ Inadequate response

   Briefly describe details of adverse reaction or inadequate response.

4. Is the member stable on the requested prescription drug prescribed by the health care provider, and switching drugs will likely cause an adverse reaction in or physical or mental harm to the member?

   ☐ Yes. Please provide details.
   ☐ No

Please continue to next page and complete Prescriber and Provider Information section.

Prior Authorization Request Prescriber and Provider Information

Prescriber Information

Last name* First name* MI

NPI* Individual MH Provider ID

DEA No. Office Contact Name

Address City State Zip

Email address

Telephone No.* Fax No.*

** Required*

Please also complete for professionally administered medications, if applicable.

Start date End date

Servicing prescriber/facility name ☐ Same as prescribing provider

Servicing provider/facility address

Servicing provider NPI/tax ID No.

Name of billing provider

Billing provider NPI No.

Is this a request for recertification? ☐ Yes ☐ No

CPT code No. of visits J code No. of units

Prescribing provider's attestation, signature, and date

I certify under the pains and penalties of perjury that I am the prescribing provider identified in the Prescriber information section of this form. Any attached statement on my letterhead has been reviewed and signed by me. I certify that the medical necessity information (per 130 CMR 450.204) on this form is true, accurate, and complete, to the best of my knowledge. I understand that I may be subject to civil penalties or criminal prosecution for any falsification, omission, or concealment of any material fact contained herein.

Prescribing provider's signature _____

Printed name of prescribing provider Date

(The form can either be signed by hand and then scanned, or it can be signed electronically using DocuSign or Adobe Sign. For electronic signatures, the signer can upload a picture of their wet signature. The typed text of a signature is not an acceptable form of an electronic signature.)